Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 41CNS 35Gastrointestinal 32Breast 29Lymphoid 14Head & Neck 12Gynecologic 10Thoracic 8Other hematologic neoplasm 7Sarcoma 6Tumor-Agnostic 5Other solid neoplasm 5Plasma cell 2Myeloid 2Endocrine 2Dermatologic 2

Conditions

Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Magnetic Resonance Imaging × Dermatologic × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01557881 2020-02-24

Positron Emission Tomography/Magnetic Resonance Imaging in Patients

Case Comprehensive Cancer Center

Phase NA Terminated
98 enrolled 5 charts
DermatologicGastrointestinalHead & NeckLymphoidThoracic

Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡